Amgen Reveals First Figures For US Humira Rival
Q1 Sales Disclosed For Amjevita Biosimilar As Brand Loses A Quarter Of Value In US
Executive Summary
As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.
You may also be interested in...
Senderra Rolls Out Five Humira Biosimilars Across Its Network
Senderra Specialty Pharmacy is the latest service provider to announce expanding access to adalimumab products, making five Humira biosimilars available across its network.
The Next Wave Of US Humira Biosimilars
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.
Generics Bulletin Explains: The Next Wave Of US Humira Biosimilars
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.